Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.
Iambic Therapeutics plans to raise $150 millions by issuing 9.4 million shares, with an offering price range of $15 to $17 per share.
According to Golden Ten Data APP, Iambic Therapeutics (IAM.US), a clinical-stage biotechnology company based in San Diego, California that develops small molecule anti-cancer therapies using its proprietary artificial intelligence (AI) platform, announced its IPO terms on Thursday. The company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17 per share. Some investors have indicated interest in subscribing for $60 million worth of shares in this offering (accounting for 40% of the transaction). Based on the midpoint of the proposed price range, Iambic Therapeutics’ fully diluted market capitalization would reach $809 million.
Iambic Therapeutics is a clinical-stage biotechnology company that combines proprietary AI models with automated high-throughput chemistry and biology to design small molecule drugs. The platform operates a closed-loop process: its models propose compound candidates, the robotic lab synthesizes and tests hundreds of compounds for each project weekly, and the resulting data is used to retrain the models. Its main drug candidate, IAM1363, is a selective, blood-brain barrier-penetrant HER2 inhibitor, currently undergoing Phase 1/1b clinical trials for HER2-altered solid tumors, with registrational trials potentially beginning as early as 2027; two other preclinical projects targeting KIF18A and CDK2/4 are planned to submit IND applications in the fourth quarter. To date, Iambic Therapeutics has generated revenue through collaborations with companies such as AbbVie (ABBV.US), Takeda Pharmaceuticals (TAK.US), and Bayer (BAYRY.US).
Iambic Therapeutics was founded in 2019 and achieved $18 million in revenue over the 12 months ending June 30, 2026. The company plans to list on Nasdaq under the ticker IAM. JPMorgan, Jefferies, BofA Securities, and Citi are serving as joint bookrunners for this offering. Pricing is expected during the week of October 12, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - RBC expects gradual improvement in North American and European building materials stocks in the third quarter
October 9 - RBC expects the performance of most European building material products to gradually improve quarter-on-quarter in Q3, but notes that geopolitical uncertainties in the US will continue to drive up cost inflation and increase market volatility. RBC anticipates that sales in Europe will remain sluggish due to heatwaves and rising mortgage rates, while a weak US housing market and the lack of a significant hurricane season will prompt roofing material companies to enter a destocking cycle. The firm is more optimistic about Germany’s Heidelberg Group (HEIG.DE), upgrading its rating to “outperform,” and points out that the company has handled the challenging quarter caused by extreme weather far better than its peers. Due to severe cost headwinds such as rising diesel and natural gas prices, RBC downgraded the ratings of US and French construction companies Knife River (KNF.N) and Saint-Gobain (SGOB.PA) from “outperform” to “market perform.” (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translations may contain errors or lack necessary context, Reuters does not guarantee their accuracy and provides them solely for the ease of the reader. Reuters assumes no liability for any damages or losses that may arise from the use of automated translation functions.)
3D printing materials supplier Amaero (AMRO.US) restarts US IPO, fundraising drops 60% to $20 million
Amaero (AMRO.US) on Thursday resumed its initial public offering (IPO) plans in the United States and filed new documents with the U.S. Securities and Exchange Commission (SEC), revealing a reduced number of shares to be issued.
Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.
Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.
Crypto prices
More
